RLS3 belongs to this class, which interacts with the GPX4 selenocysteine, irreversibly inhibiting the enzyme activity [25], as well as several exponents of the class II FINS (DPI7, DPI10, DPI12, DPI13, DPI17, DPI18 and DPI19) and altretamine, an FDA-approved anti-cancer compound [23,24,26,27]. The gene discussed is GPX4; the disease is cancer.